MDAI: Difference between revisions
From DMT-Nexus Wiki
Jump to navigationJump to search
No edit summary |
|||
| Line 13: | Line 13: | ||
== Brief overview - What is MDAI? == | == Brief overview - What is MDAI? == | ||
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects | 5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects. | ||
Revision as of 21:17, 19 December 2013
| Safety profile |  |
|---|---|
Category:
|
|
Main effects:
|
|
Side effects:
|
|
Health risks:
|
|
Important safety remarks:
|
|
Brief overview - What is MDAI?
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.
